dw-mri as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomadw-mri作为生物标志物来比较治疗效果在放射治疗方案将temozolomide或吉西他滨在胶质母细胞瘤.pdfVIP

下载本文档

7
0
约6.47万字
约 11页
2017-09-12 发布于上海
举报

dw-mri as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomadw-mri作为生物标志物来比较治疗效果在放射治疗方案将temozolomide或吉西他滨在胶质母细胞瘤.pdf

dw-mri as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomadw-mri作为生物标志物来比较治疗效果在放射治疗方案将temozolomide或吉西他滨在胶质母细胞瘤

DW-MRI as a Biomarker to Compare Therapeutic Outcomes in Radiotherapy Regimens Incorporating Temozolomide or Gemcitabine in Glioblastoma ´ 1 2 1 2 2 Stefanie Galban , Benjamin Lemasson , Terence M. Williams , Fei Li , Kevin A. Heist , 3 1 1 2 Timothy D. Johnson , Judith S. Leopold , Thomas L. Chenevert , Theodore S. L

您可能关注的文档

文档评论（0）

1亿VIP精品文档

更多 >

dw-mri as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastomadw-mri作为生物标志物来比较治疗效果在放射治疗方案将temozolomide或吉西他滨在胶质母细胞瘤.pdfVIP